GeneLeap Biotechnology

GeneLeap Biotechnology is a clinical-stage biopharmaceutical company specializing in the discovery and development of RNA-based therapeutics and gene therapies. As a subsidiary of Luye Life Sciences Group, the company leverages its proprietary mRNA synthesis and lipid nanoparticle (LNP) delivery platforms to address unmet medical needs in oncology, infectious diseases, and genetic disorders. Its lead program, LY01620, is a therapeutic mRNA vaccine targeting HPV16-positive cervical lesions, currently in Phase 1 clinical trials. GeneLeap also advances a diverse pipeline including oligonucleotide-based TLR9 agonists for immuno-oncology and AAV-based gene therapies for neurological and ophthalmic conditions. With research and development facilities in Nanjing, China, and the United States, the company is positioned as a global player in the rapidly evolving field of genomic medicine.